Early Remdesivir for Patients Who Are Immunocompromised and Hospitalized With COVID-19
Open Forum Infectious Diseases · 31.10.2026 · 13 (11)
DOI: 10.1093/ofid/ofag630 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 04.11.2026. Verfasst von Kathleen E Hurwitz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Epidemiology, Headwater Science, Durham, North Carolina, USA. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences Inc.
Abstract (Originalsprache)
Background
Patients who were immunocompromised were largely excluded from COVID-19 clinical trials, and real-world evidence on remdesivir effectiveness has produced conflicting results. We evaluated whether early remdesivir initiation (vs late or never) reduces in-hospital mortality among patients who are immunocompromised and hospitalized with COVID-19.
Methods
We conducted a retrospective cohort study using a target trial emulation framework with clone-censor-weighting and deidentified hospital chargemaster data combined with medical and pharmacy claims from approximately 400 US hospitals. Patients included those who were immunocompromised, aged ≥12 years, and hospitalized for COVID-19 between 1 May 2020 and 3 December 2023. We assessed all-cause in-hospital mortality within 14 and 28 days of admission for 3 remdesivir treatment regimens: initiation within 2 days of admission (“early”), initiation within 3 to 7 days (“late”), and no initiation of remdesivir (“never”).
Results
Among 97 587 eligible patients (median age, 71 years; 51% female), the 14-day cumulative risk of in-hospital mortality was 9.2% for early remdesivir, 10.1% for late, and 11.8% for never. At 14 days, the adjusted relative risk was 0.91 (95% CI, .86–.97) for early vs late initiation and 0.78 (95% CI, .75–.81) for early vs never initiation. At 28 days, trends were similar. Subgroup analyses by age, variant era, and immunosuppression severity yielded similarly protective effects of early initiation of remdesivir.
Conclusions
The risk of in-hospital mortality for patients with COVID-19 who were immunocompromised was lower when remdesivir was administered early as compared with late or never. This result was consistent regardless of age, severity of immunosuppression, and variant era.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Epidemiology, Headwater Science, Durham, North Carolina, USA.
- Virology, Gilead Sciences, Foster City, California, USA.
- Department of Population Health Sciences, Duke University, Durham, North Carolina, USA.
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Mark Berry, Nuvan Rathnayaka, Mazin Abdelghany, Carrie M Nielson, Joshua A Hill
Förderung
- Gilead Sciences Inc
Zitieren
APA
Hurwitz, K. E., Berry, M., Lee, E., Hendrickson, K., Rathnayaka, N., Shvachko, V., Abdelghany, M., Nielson, C. M., Brookhart, M. A., Chokkalingam, A., & Hill, J. A. (2026). Early Remdesivir for Patients Who Are Immunocompromised and Hospitalized With COVID-19. Open Forum Infectious Diseases, 13(11). https://doi.org/10.1093/ofid/ofag630
Vancouver
Hurwitz KE, Berry M, Lee E, Hendrickson K, Rathnayaka N, Shvachko V, et al. Early Remdesivir for Patients Who Are Immunocompromised and Hospitalized With COVID-19. Open Forum Infectious Diseases. 2026;13(11). doi:10.1093/ofid/ofag630
BibTeX
@article{Hurwitz2026,
author = {Hurwitz, Kathleen E and Berry, Mark and Lee, EunYoung and Hendrickson, Kayla and Rathnayaka, Nuvan and Shvachko, Valentina and Abdelghany, Mazin and Nielson, Carrie M and Brookhart, M Alan and Chokkalingam, Anand and Hill, Joshua A},
title = {Early Remdesivir for Patients Who Are Immunocompromised and Hospitalized With COVID-19},
journal = {Open Forum Infectious Diseases},
year = {2026},
volume = {13},
number = {11},
doi = {10.1093/ofid/ofag630}
}
EUVIMED